19 December 2019
Visiongain has launched a new pharma report Global Norovirus Vaccines in Pipeline Forecast 2020-2030: Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics.
Norovirus has become the leading cause of medically attended acute gastroenteritis and is a common cause of outbreaks worldwide. There is no licensed norovirus vaccine yet, but there are promising candidate vaccines in the pipeline. This burden affects children under 5 years of age and people in developing countries overwhelmingly.
The lead analyst of the report commented "Despite external stimuli, such as a major donor, developed global markets are likely to provide the initial economic support for the production of norovirus vaccines for private industry. Early phase trials among adults in high-income settings have been conducted to date, leaving a need for a paediatric development plan."
Leading companies featured in the report include Takeda, Vaxart, Cocrystal Pharma, PanTheryx, Calici Therapeutics and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.
06 May 2021
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.
05 May 2021
Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.
29 April 2021
Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.